Company to run a Phase 2 clinical study with LAU-7b, a pro-resolving drug with potential antiviral properties against coronavirus

Classified as: anti-viral drugs, Clinical trials, press release, covid-19, therapies
Published on: 9 Apr 2020

A Canadian research team at the IRCM in Montréal, led by molecular virologist Éric A. Cohen, PhD, made a significant discovery on how HIV escapes the body’s antiviral responses. The team uncovered how an HIV viral protein known as Vpu tricks the immune system by using its own regulatory process to evade the host’s first line of defence. This breakthrough was published yesterday in the scientific journal PLoS Pathogens and will be presented at the upcoming IAS 2015 conference in Vancouver. The findings pave the way for future HIV prevention or cure strategies.

Classified as: McGill, health, HIV, AIDS, immune system, IRCM, eric a. cohen, anti-viral drugs
Category:
Published on: 15 Jul 2015
Back to top